




RealRate

PHARMACEUTICAL 2020

Sonnet BioTherapeutics Holdings Inc. Rank 291 of 358





RealRate

PHARMACEUTICAL 2020

Sonnet BioTherapeutics Holdings Inc. Rank 291 of 358



The relative strengths and weaknesses of Sonnet BioTherapeutics Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonnet BioTherapeutics Holdings Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Sonnet BioTherapeutics Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is -71%, being 107% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	1,170
Cost of Goods Sold	0
Intangible Assets	12,225
Liabilities, Current	18,095
Liabilities, Non-Current	15,342
Other Assets	12,508
Other Compr. Net Income	894
Other Expenses	40,329
Other Liabilities	1,248
Other Net Income	-2,313
Other Revenues	30,143
Property and Equipment	5,630
Research and Development	0
Selling, General and Administrative Expense	5,966

Output Variable	Value in 1000 USD
Assets	31,533
Liabilities	34,685
Expenses	46,295
Revenues	30,143
Stockholders Equity	-3,152
Net Income	-18,465
Comprehensive Net Income	-18,018
Economic Capital Ratio	-71%